Who is sponsoring NCT00138086?

NCT00138086 is sponsored by Lymphoma Study Association.

What condition does NCT00138086 study?

NCT00138086 studies B-Cell Lymphoma.

What drugs are being tested in NCT00138086?

Interventions: Zevalin plus BEAM.

What is the status of NCT00138086?

NCT00138086 is currently COMPLETED.

Last reviewed 2006-09-06 · How we verify

Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT)

NCT00138086 Phase 2 COMPLETED

The objective of this study is to evaluate the efficacy and the safety of Zevalin-BEAM preparative regimen before autologous stem cell transplantation (ASCT) as measured by the event free survival (EFS). The goal is to obtain a 15% increase of EFS at 2 years.

Details

Lead sponsor	Lymphoma Study Association
Phase	Phase 2
Status	COMPLETED
Enrolment	75
Start date	2005-03
Completion	2009-03

Conditions

B-Cell Lymphoma

Interventions

Zevalin plus BEAM

Primary outcomes

EFS (event free survival)

Countries

Belgium, France, Switzerland